This is the authors' abstract. We don't add key points for this paper.
Naloxegol is a peripherally acting μ-opioid receptor antagonist that was developed for the treatment of opioid-induced constipation. Modeling and simulation of naloxegol efficacy and tolerability informed selection of doses for phase III studies and provided comprehensive dosage recommendations for the naloxegol US package insert.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Al‐Huniti et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: